Jardiance Cost in Maine 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Jardiance Actually Cost in Maine in 2026?

Brand-name Jardiance carries a manufacturer list price of approximately $680 per month in 2026, a figure consistent across Maine retail chains including Hannaford Pharmacy, Walgreens, and CVS locations statewide. Without insurance or a savings program, that price is what a cash-paying patient faces at the counter.

Retail pricing in Maine follows national average wholesale price (AWP) benchmarks set by Boehringer Ingelheim and Eli Lilly, who co-commercialize empagliflozin under the Jardiance brand. The FDA approved empagliflozin in August 2014 for glycemic control in type 2 diabetes, with subsequent approvals for heart failure and chronic kidney disease expanding its use considerably. Full prescribing information is available from the FDA.

GoodRx and similar discount aggregators can bring the out-of-pocket price to approximately $530 to $600 per month at select Maine pharmacies, depending on the specific location and current coupon availability. That still represents a significant annual expense of roughly $6,360 to $8,160 for a patient without meaningful insurance coverage.

The price gap between brand-name Jardiance and compounded empagliflozin is wide. Compounded formulations from licensed 503A pharmacies routinely cost $80 to $200 per month depending on dose, and some telehealth programs that bundle the consultation fee offer it at effectively no additional cost per month once the care plan is active. Maine law permits this, as described in the section on compounding below.

Generic empagliflozin remains unavailable in the United States as of mid-2025. Boehringer Ingelheim holds exclusivity through at least 2025, and no FDA-approved generic has an established launch date. Patients should confirm current generic availability with their pharmacist before assuming a lower-cost generic option exists. FDA Orange Book listings track exclusivity status in real time.

Does Maine Medicaid (MaineCare) Cover Jardiance?

MaineCare covers empagliflozin with prior authorization for three FDA-approved indications: type 2 diabetes mellitus, heart failure, and chronic kidney disease. The prior authorization requirement means a prescriber must submit documentation showing the patient meets clinical criteria before MaineCare will pay for the drug.

For type 2 diabetes, MaineCare generally requires evidence of an HbA1c above a defined threshold and documentation that metformin was tried or is contraindicated. For heart failure and CKD indications, documentation of the relevant diagnosis along with relevant lab values (eGFR, NT-proBNP, or echocardiographic data) typically satisfies the authorization criteria. Prescribers should consult the current MaineCare Benefits Manual, Chapter II, Section 80 for the exact preferred drug list and PA criteria, as these are updated quarterly.

Patients on MaineCare who are denied coverage for empagliflozin can appeal through the MaineCare fair hearing process. Approval rates on first-level appeals for SGLT2 inhibitors with documented cardiovascular or renal indications have been favorable nationally, given the strength of trial data supporting cardiovascular and renal outcomes benefits. The EMPA-REG OUTCOME trial demonstrated a 38% relative risk reduction in cardiovascular death and a 35% relative risk reduction in hospitalization for heart failure among adults with type 2 diabetes and established cardiovascular disease, findings that now form the backbone of guideline-directed prescribing. [1]

The 2023 American Diabetes Association Standards of Care recommend empagliflozin as a preferred agent for patients with type 2 diabetes who also have established atherosclerotic cardiovascular disease, heart failure, or CKD, independent of baseline HbA1c. [2] That guideline language strengthens prior authorization arguments when MaineCare coverage is challenged.

Low-income MaineCare members who also qualify for Medicare Part D (dual eligibles) face different formulary rules under their Part D plan. Most Part D plans place Jardiance on Tier 3 or Tier 4, meaning even dual-eligible patients may face cost-sharing unless they receive Low Income Subsidy (LIS) benefits, which cap drug costs at nominal amounts.

Is Compounded Empagliflozin Legal in Maine?

Compounded empagliflozin from a state-licensed 503A pharmacy is legal in Maine. A 503A pharmacy compounds medications for individual patients upon receipt of a valid prescription from a licensed prescriber. Maine follows federal law under the Drug Quality and Security Act, which permits 503A compounding using bulk active pharmaceutical ingredients (APIs) that are not on the FDA's list of prohibited substances.

Empagliflozin API is not currently on the FDA's Category 1 (prohibited) or Category 2 (under evaluation) lists for 503A compounding as of this writing, meaning licensed Maine compounding pharmacies may prepare it. FDA guidance on 503A compounding outlines the regulatory framework. [3]

The distinction between 503A and 503B matters here. A 503B outsourcing facility can compound in bulk for distribution without patient-specific prescriptions, but 503A pharmacies need an individual prescription for each patient. Most telehealth-connected compounding services operating in Maine use 503A pharmacies. Patients should verify that any pharmacy filling their compounded empagliflozin holds an active Maine pharmacy license, which is searchable through the Maine Board of Pharmacy.

Compounded empagliflozin is not FDA-approved and has not been evaluated in the same clinical trials as brand-name Jardiance. Quality, purity, and dose accuracy depend entirely on the compounding pharmacy's standards. Reputable 503A pharmacies conduct independent third-party testing and publish certificates of analysis. Asking for this documentation is reasonable and appropriate before starting therapy.

The HealthRX clinical team uses a four-criteria framework when evaluating whether a Maine patient is a good candidate for compounded empagliflozin rather than brand-name Jardiance:

1. No active insurance coverage or insurance denial after appeal, and cash-pay cost exceeds $400/month.
2. Prescriber has verified the 503A pharmacy's current Maine license and reviewed a certificate of analysis for the empagliflozin batch.
3. Patient has a confirmed diagnosis (T2D, HF, or CKD) with baseline labs (eGFR, HbA1c or BNP) on file.
4. Follow-up labs are scheduled within 90 days of starting, given SGLT2 inhibitors' known effects on eGFR (an initial small dip of approximately 3 to 5 mL/min/1.73 m² that is expected and does not indicate drug discontinuation per KDIGO 2024 guidelines). [4]

Patients who meet all four criteria are generally appropriate candidates. Those who have commercial insurance with manageable copays or who qualify for the manufacturer savings card described below should usually start with brand-name Jardiance first.

Which Insurance Plans Cover Jardiance in Maine?

Most commercial insurance plans sold on the Maine state exchange (accessible via HealthCare.gov) cover empagliflozin, though tier placement and cost-sharing vary by plan. Anthem Blue Cross Blue Shield, Harvard Pilgrim (which merged with Tufts Health Plan under Point32Health), and Aetna are among the largest insurers offering individual and employer-sponsored plans in Maine. Each places Jardiance on Tier 3 to Tier 4 of their formularies, translating to copays that typically range from $60 to $180 per month after deductible.

Step therapy is common. Many Maine commercial plans require documented trial and failure of metformin before approving Jardiance for type 2 diabetes, and some require a prior SGLT2 inhibitor trial. For heart failure or CKD indications without diabetes, step therapy requirements are generally less stringent because there are fewer therapeutic alternatives with equivalent trial evidence.

The EMPEROR-Reduced trial (N=3,730) established empagliflozin 10 mg as reducing the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo in patients with heart failure with reduced ejection fraction, data that insurers now recognize as supporting the heart failure indication. [5] The EMPEROR-Preserved trial (N=5,988) extended those findings to heart failure with preserved ejection fraction, showing a 21% relative risk reduction in the same composite endpoint. [6]

For Medicare Part D specifically, Jardiance appears on most Maine-available Part D plans' formularies. CMS data show that in plan year 2025, roughly 85% of Part D stand-alone drug plans nationally listed at least one SGLT2 inhibitor. Patients should use the Medicare Plan Finder to compare specific formulary placement and cost-sharing for their zip code in Maine, because tier placement and copays differ between plans even within the same county.

Employers with self-insured plans in Maine have discretion over their formularies and may negotiate direct rebates with Boehringer Ingelheim, sometimes making Jardiance available at lower effective cost than exchange plans. Employees should check with their HR benefits department or review their Summary of Benefits and Coverage document.

How the Boehringer Ingelheim/Lilly Savings Card Works in Maine

The Jardiance Savings Card program, operated jointly by Boehringer Ingelheim and Eli Lilly, allows eligible commercially insured patients to pay as little as $10 per month for a 30-day supply. The card covers the gap between the patient's insurance copay and the full retail price, up to a defined annual maximum benefit (currently $150 per fill or $1,800 per year, though program terms change and should be verified at jardiance.com).

The savings card is not available to patients enrolled in Medicare, Medicaid (including MaineCare), TRICARE, or any other federal or state government health program. This restriction is a federal legal requirement, not a manufacturer discretion. Patients who are dual-eligible (Medicare plus MaineCare) cannot use the savings card.

Uninsured patients and those who don't qualify for the savings card may access the Boehringer Ingelheim Patient Assistance Program, which provides Jardiance at no cost to qualifying patients based on income and insurance status. Income thresholds vary by household size. Enrollment requires a prescriber signature and documentation of income. Processing typically takes two to four weeks.

For Maine patients who face a coverage gap during the Part D donut hole, the standard coverage gap discount of 70% from the manufacturer applies automatically at the pharmacy. The Inflation Reduction Act has modified Part D cost-sharing structure for 2025 and beyond, so Maine Medicare beneficiaries should confirm their specific out-of-pocket maximum with 1-800-MEDICARE. [7]

How Telehealth Prescribing of Jardiance Works in Maine

Maine law permits telehealth prescribing of scheduled and non-scheduled prescription drugs, including empagliflozin, provided that the prescriber establishes a valid patient-provider relationship. Under Maine's telehealth statute (22 M.R.S. §3173-C), that relationship may be established through synchronous audio-visual encounter, meaning a video visit fully satisfies the requirement. [8]

A prescriber licensed in Maine (or holding a multi-state compact license that includes Maine) may prescribe Jardiance via telehealth after conducting an appropriate clinical assessment. That assessment should include review of relevant history, current medications, contraindications (eGFR <20 mL/min/1.73 m² is a contraindication for the CKD indication; eGFR <30 is a contraindication for initiation for glycemic control per FDA labeling), and baseline lab values. [9]

Maine joined the Interstate Medical Licensure Compact, which allows physicians licensed in a member state to obtain expedited licensure in other member states. Telemedicine companies operating across state lines in Maine should confirm their prescribers hold valid Maine licenses or compact licenses. Patients can verify a prescriber's Maine license at the Maine Board of Licensure in Medicine.

HealthRX connects Maine patients with board-certified clinicians who can evaluate candidacy for empagliflozin via video visit, order baseline labs through a Maine-accessible lab network, and route prescriptions to either a local Maine pharmacy or a licensed compounding pharmacy depending on the patient's coverage situation.

What Are the Clinical Benefits That Drive Prescribing?

Empagliflozin's cost is only one part of the decision. The clinical trial record is one of the strongest in modern cardiology and nephrology, and understanding it helps patients and prescribers justify insurance appeals and shared decision-making conversations.

EMPA-REG OUTCOME (N=7,020) published in the New England Journal of Medicine in 2015 showed that empagliflozin 10 mg or 25 mg reduced the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% relative to placebo (HR 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) in adults with type 2 diabetes and established cardiovascular disease. [1] Cardiovascular death specifically fell by 38%, a result that shifted prescribing guidelines internationally.

The EMPA-KIDNEY trial (N=6,609) published in 2023 demonstrated that empagliflozin 10 mg reduced the risk of progression of kidney disease or cardiovascular death by 28% relative to placebo across a wide range of eGFR values (as low as 20 mL/min/1.73 m²), establishing its benefit in CKD regardless of diabetes status. [10] The FDA granted a supplemental indication for CKD based substantially on EMPA-KIDNEY data. [11]

The 2022 AHA/ACC/HFSA Heart Failure Guideline assigns SGLT2 inhibitors a Class I recommendation (Level of Evidence: A) for patients with symptomatic chronic heart failure and reduced ejection fraction, stating: "SGLT2i are recommended in patients with symptomatic chronic HFrEF to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of T2D." [12] That guideline quotation gives prescribers unambiguous language for prior authorization letters in Maine.

The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD recommends empagliflozin or another SGLT2 inhibitor for patients with type 2 diabetes and CKD who have eGFR >20 mL/min/1.73 m², with a Grade 1A recommendation (strong; high-quality evidence). [4]

Common adverse effects include urinary tract infections, genital mycotic infections, and the rare but serious diabetic ketoacidosis (DKA). DKA risk is higher during fasting, surgical procedures, or severe illness. Patients should hold empagliflozin 3 to 4 days before elective surgery per Endocrine Society guidance. [13]

Practical Steps for Maine Patients in 2026

Getting empagliflozin at the lowest legal cost in Maine involves a clear sequence. First, confirm your diagnosis and whether you meet one of the three FDA-approved indications: type 2 diabetes, heart failure, or chronic kidney disease. FDA labeling specifies eGFR cutoffs for each indication. [11]

Second, check your specific insurance formulary. For MaineCare, request a prior authorization from your prescriber before the first fill. For commercial plans, ask your pharmacist to run a benefits check with the savings card applied. Many Maine patients with commercial insurance pay $10 to $50 per month after combining insurance coverage and the Boehringer Ingelheim savings card.

Third, if you are uninsured or underinsured, ask your prescriber specifically about compounded empagliflozin from a Maine-licensed 503A pharmacy. Verify the pharmacy's license and request a certificate of analysis for the batch. The National Association of Boards of Pharmacy (NABP) recommends checking that any compounding pharmacy is licensed and in good standing. [3]

Fourth, schedule baseline labs before or within two weeks of starting: comprehensive metabolic panel (including creatinine and eGFR), HbA1c if diabetic, and urinalysis. Repeat eGFR at 8 to 12 weeks. An expected initial eGFR dip of 3 to 5 mL/min/1.73 m² does not require stopping the drug and predicts long-term renal protection per EMPA-KIDNEY and CREDENCE trial data. [10]

Patients who have a confirmed heart failure diagnosis should have their NT-proBNP or BNP reviewed at baseline and at 3 months to assess response. The EMPEROR-Reduced trial showed statistically significant NT-proBNP reduction at 12 weeks in the empagliflozin arm versus placebo (geometric mean ratio 0.85, P<0.001), a measurable marker clinicians and patients can track. [5]